Sanegene Bio develops an RNAi drug discovery platform designed for unmet clinical needs.
Sanegene Bio has raised $110.0M in total funding. The most recent round was Series B. The last funding was announced in December 2025.
Sanegene Bio's investors include Qiming Venture Partners, Shenzhen Capital Group, Eli Lilly, Legend Capital, Vivo Capital.
Sanegene Bio is headquartered in Woburn, United States.
Sanegene Bio develops an RNAi drug discovery platform designed for unmet clinical needs.
Sanegene Bio is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Sanegene Bio — Funding & Investors." VCBacked, December 8, 2025, https://www.vcbacked.co/company/sanegene-bio. Accessed July 19, 2026.
VCBacked. (2025). Sanegene Bio — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/sanegene-bio
{{cite web |title=Sanegene Bio — Funding & Investors |url=https://www.vcbacked.co/company/sanegene-bio |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated